Market Closed -
Nasdaq
01:30:00 16/05/2024 am IST
5-day change
1st Jan Change
26.22
USD
+1.90%
+14.00%
-14.00%
This article is reserved for members
Not a member ?
Free registration
Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises
09/05
MT
Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05
Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
09/05
CI
Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer
16/04
CI
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals
25/03
MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals
22/03
MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron
22/03
DJ
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
18/03
CI
Transcript : Intellia Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM
14/03
North American Morning Briefing : Traders Await -2-
26/02
DJ
Canaccord Genuity Adjusts Price Target on Intellia Therapeutics to $73 From $72, Maintains Buy Rating
23/02
MT
Intellia Therapeutics Q4 Loss Widens
22/02
MT
Transcript : Intellia Therapeutics, Inc., Q4 2023 Earnings Call, Feb 22, 2024
22/02
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
22/02
CI
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
22/02
CI
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis
16/02
MT
Wolfe Research Starts Intellia Therapeutics With Peer Perform Rating
15/02
MT
Intellia Therapeutics, Inc. and ReCode Therapeutics Announces Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
15/02
CI
Intellia Therapeutics Says Investigational Hereditary Angioedema Treatment Shows Promise in Phase 1 Study
01/02
MT
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
01/02
CI
Transcript : Intellia Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05:15 PM
10/01
Intellia Therapeutics Insider Sold Shares Worth $566,310, According to a Recent SEC Filing
06/01
MT
Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees
06/12
CI
Intellia Therapeutics Files Mixed Shelf
27/11
MT
Intellia Therapeutics Receives EU Orphan Drug Designation for Hereditary Angioedema Candidate Therapy
14/11
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
More about the company
Last Close Price
26.22
USD
Average target price
70.26
USD
Spread / Average Target
+167.96%
Consensus
1st Jan change
Capi.
-14.00% 2.53B +29.77% 49.46B +1.00% 42.58B +49.84% 42.49B -5.26% 29.09B +13.68% 26.61B -22.99% 18.64B +8.22% 13.16B +32.41% 12.55B -1.62% 11.98B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**